Key Takeaways:
Tokyo, Japan and Cambridge, UK – Nxera Pharma's partner Neurocrine Biosciences has dosed the first patient in a Phase 2 clinical trial of NBI-1117570, an investigational treatment for adults with schizophrenia. The start of the trial triggers a $22.5 million milestone payment to Nxera from Neurocrine.
"The dosing of the first patient in this Phase 2 trial is a significant step forward for NBI-1117570 and our collaboration with Neurocrine," said a spokesperson for Nxera Pharma.
NBI-1117570 is an investigational oral, dual muscarinic M1/M4 selective receptor agonist discovered by Nxera. It is advancing through clinical development under a multi-program collaboration with Neurocrine Biosciences. The Phase 2 trial will evaluate the efficacy and safety of the drug in adults with schizophrenia.
This milestone is a positive development for both companies. For Nxera, it provides a non-dilutive source of funding and validates its discovery platform. For Neurocrine, it represents progress in its clinical pipeline and a potential new treatment for a significant unmet medical need. Investors will be closely watching for the results of the Phase 2 trial, which are expected in 2027.
This article is for informational purposes only and does not constitute investment advice.
